Evidence map›Paper›PMID 41717416›Full record

ArticleFrontiers in oncology2026

Spinal decompression and radionuclide therapy for an unresectable FGF23 transmitted tumor causing cervical myelopathy: a case report and literature review.

Shin Yokoyama, Hirokazu Shimizu, Akiko Yuno, Junki Takenaka, Naoto Wakabayashi, Shiro Watanabe, Ken Kuwahara, Masatake Matsuoka, Tomohiro Onodera, Norimasa Iwasaki and 1 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shin YokoyamaDepartment of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hirokazu ShimizuDepartment of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Akiko YunoDepartment of Endocrinology and Metabolism, Kin-ikyo Chuo Hospital, Sapporo, Japan.
Junki TakenakaDepartment of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Naoto WakabayashiDepartment of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Shiro WatanabeDepartment of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Ken KuwaharaDepartment of Pathology, NHO Hokkaido Cancer Center, Sapporo, Japan.
Masatake MatsuokaDepartment of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Tomohiro OnoderaDepartment of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Norimasa IwasakiDepartment of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Akira IwataDepartment of Musculoskeletal Oncology, NHO Hokkaido Cancer Center, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tumor-induced osteomalacia (TIO) is a rare disorder characterized by hypophosphatemic osteomalacia, mainly caused by benign tumors with excessive secretion of fibroblast growth factor 23 (FGF23) and somatostatin receptor expression. Although complete excision is recommended, reports on treatment strategies for anatomically challenging surgical cases are lacking. We report an unresectable case of FGF23 transmitted tumor in the cervical vertebrae causing myelopathy, which was treated with surgical decompression combined with radionuclide therapy. Case presentation: A 52-year-old woman presented to another hospital with complaints of knee pain. After confirming abnormal tracer uptake at the C7 vertebrae using somatostatin receptor scintigraphy and an elevated serum FGF23 level (>800 pg/mL), TIO was diagnosed 7 years after the initial presentation. Gait disturbance occurred 10 years after the initial presentation; therefore, the patient was referred to our department. Magnetic resonance imaging revealed a tumor with spinal cord compression and vertebral artery encasement, making complete resection impossible. Gait disturbance improved after spinal decompression with partial resection of the tumor. Peptide receptor radionuclide therapy targeting somatostatin receptors was initiated 2 years after surgery. Serum phosphate levels normalized, and the tumor size remained stable after the initiation of PRRT. Ambulation was maintained without joint pain recurrence at 3 years after surgery. Conclusions: The current literature on FGF23 transmitted tumors in the cervical spine includes six cases treated with definitive local therapy. This case suggests an alternative option for unresectable FGF23 transmitted tumor in the vertebrae, causing spinal myelopathy.

Indexed as

cervical myelopathyFGF23 transmitted tumorpeptide receptor radionuclide therapyspinal decompressionunresectable case

Identifiers

PMID41717416
PMCPMC12913124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.